Propanc Biopharma annual stock-based compensation
2016
2017
2018
2020
2021
2022
2023
2024
2025
Propanc Biopharma Stock-Based Compensation Growth & History (PPCB)
Propanc Biopharma's stock-based compensation was $4.6M for fiscal 2025.
View full Propanc Biopharma company overviewPropanc Biopharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $4.6M | $4.6M | — |
| 2024 | 2024-06-30 | $0 | −$2,408 | — |
| 2023 | 2023-06-30 | $2,408 | −$70,105 | −96.68% |
| 2022 | 2022-06-30 | $72,513 | −$10,359 | −12.50% |
| 2021 | 2021-06-30 | $82,872 | −$217,544 | −72.41% |
| 2020 | 2020-06-30 | $300,416 | — | — |
| 2018 | 2018-06-30 | $516,148 | −$1.2M | −69.39% |
| 2017 | 2017-06-30 | $1.7M | −$35,844 | −2.08% |
| 2016 | 2016-06-30 | $1.7M | — | — |
Propanc Biopharma quarterly stock-based compensation
Q1.18
Q2.18
Q3.18
Q4.18
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q3.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | $1.8M | −$51.1M | −96.64% |
| Q2 2026 | 2025-12-31 | $2.5M | — | — |
| Q1 2026 | 2025-09-30 | $3.0M | — | — |
| Q3 2025 | 2025-03-31 | $52.8M | — | — |
| Q4 2023 | 2023-06-30 | $0 | −$10,359 | — |
| Q3 2023 | 2023-03-31 | $0 | −$20,718 | — |
| Q2 2023 | 2022-12-31 | $0 | −$20,718 | — |
| Q1 2023 | 2022-09-30 | $2,408 | −$18,310 | −88.38% |
| Q4 2022 | 2022-06-30 | $10,359 | −$10,359 | −50.00% |
| Q3 2022 | 2022-03-31 | $20,718 | $0 | 0.00% |
| Q2 2022 | 2021-12-31 | $20,718 | $0 | 0.00% |
| Q1 2022 | 2021-09-30 | $20,718 | $0 | 0.00% |
| Q4 2021 | 2021-06-30 | $20,718 | −$123,358 | −85.62% |
| Q3 2021 | 2021-03-31 | $20,718 | $0 | 0.00% |
| Q2 2021 | 2020-12-31 | $20,718 | $0 | 0.00% |
| Q1 2021 | 2020-09-30 | $20,718 | −$94,186 | −81.97% |
| Q4 2020 | 2020-06-30 | $144,076 | — | — |
| Q3 2020 | 2020-03-31 | $20,718 | — | — |
| Q2 2020 | 2019-12-31 | $20,718 | — | — |
| Q1 2020 | 2019-09-30 | $114,904 | — | — |
| Q4 2018 | 2018-06-30 | $25,090 | — | — |
| Q3 2018 | 2018-03-31 | $161,297 | — | — |
| Q2 2018 | 2017-12-31 | $164,880 | — | — |
| Q1 2018 | 2017-09-30 | $164,881 | — | — |
Propanc Biopharma stock-based compensation trends
Over the last five fiscal years, Propanc Biopharma's stock-based compensation increased from $300,416 to $4.6M, a change of $4.3M. The latest reported quarter, Q3 2026, shows $1.8M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Propanc Biopharma source filings ↗